TARGET: A Phase I/II Open-Label Multicenter Study to Assess Safety and Efficacy of Fexagratinib in Patients with Relapsed/refractory FGFR Fusion-Positive Glioma Alberto Picca , Anna Luisa Di Stefano , Julien Savatovsky , Francois Ducray , Olivier Chinot , Elisabeth Cohen-Jonathan Moyal , Paule Augereau , Emilie Le Rhun , Yohann Schmitt , Nabila Rousseaux , Ariane Murielle Mbekwe Yepnang , Candice Estellat , Frederique Charbonneau , Quentin Letourneur , Dominique Figarella Branger , David Meyronet , Christine Fardeau , Karima Mokhtari , Franck Bielle , Antonio Iavarone , Marc Sanson Neuro-Oncology Advances（2024）
关键词
clinical trial, fexagratinib, FGFR inhibitor, FGFR3-TACC3, glioblastoma, glioma
AI 理解论文
溯源树
样例
